Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.
Lenalidomide is an immunomodulatory drug (IMiD) with activity in lymphoid malignancies occurring primarily through immune modulation (eg, T-cell immune synapse enhancement and NK-cell/T-cell effector augmentation) and antiproliferative effects. Food and Drug Administration-approved for bortezomib-resistant, relapsed/refractory mantle-cell lymphoma, lenalidomide has demonstrated efficacy in several additional lymphoma subtypes. There are many ongoing clinical trials examining the use of lenalidomide alone or in combinatorial therapy. It will be important in these studies to delineate reliable, predictive biomarkers to optimally integrate lenalidomide into lymphoma treatment paradigms.
Division of Hematology/Oncology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA.
Athena
A
Kritharis
Division of Hematology/Oncology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA.
Michael
M
Coyle
Division of Hematology/Oncology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA.
Jaya
J
Sharma
Division of Hematology/Oncology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA.
Andrew M
AM
Evens
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D000077269:Lenalidomide; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide